

Supplementary Table 1. Descriptive characteristics of eligible articles examining prognostic factors for adverse health outcomes in patients with Coronavirus-2019 disease.

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Cai, 2020 ¹	China	Guangdong	Shenzhen (Third People's Hospital of Shenzhen)	Jan 11 to Feb 6, 2020	298	Severity of COVID-19
Cao, 2020 ²	China	Hubei	Wuhan (Zhongnan Hospital)	Jan 3 to Feb 1, 2020	102	Mortality
Caruso, 2020 ³	Italy	Rome	Rome (Sant' Andrea Hospital)	March 4 to March 19, 2020	58	Severity of COVID-19
Chen, 2020 ⁴	China	Hubei	Wuhan (Tongji Hospital)	Late Dec 2019 to Jan 27, 2020	21	Severity of COVID-19
Chen, 2020 ⁵	China	Hubei	Wuhan (Tongji Hospital)	Jan 13 to Feb 12, 2020	274	Mortality
Chen, 2020 ⁶	China	Shanghai	Shanghai (Shanghai Public Health Clinical Center)	Jan 20 to Feb 6, 2020	249	ICU admission
Chen, 2020 ⁷	China	Hubei	Wuhan (Zhongnan Hospital)	Jan 1 to Feb 10, 2020	203	Mortality
Chen, 2020 ⁸	China	Hubei	Wuhan (General Hospital of People's Liberation Army)	Feb 1 to Feb 19, 2020	48	Severity of COVID-19

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Cheng, 2020 ⁹	China	Hubei	Wuhan (Tongji Hospital)	Jan 28 to Feb 11, 2020	701	Mortality
Chu, 2020 ¹⁰	China	Hubei	Wuhan (Tongji Hospital)	Jan 7 to Feb 11, 2020	54	Severity of COVID-19
Colombi, 2020 ¹¹	Italy	Emilia-Romagna	Piacenza (“Guglielmo da Saliceto” Hospital)	Feb 17 to Mar 10, 2020	236	Composite outcome
Deng, 2020 ¹²	China	Hubei	Wuhan (RenMin Hospital)	Jan 6 to Feb 20, 2020	112	Severity of COVID-19, Composite outcome
Du, 2020 ¹³	China	Hubei	Wuhan (Wuhan Pulmonary Hospital)	Dec 25, 2019 to Feb 7, 2020	179	Mortality
Du, 2020 ¹⁴	China	Hubei	Wuhan (Pulmonary Hospital of Wuhan, Tianyou Hospital, Central Hospital of Wuhan)	Dec 25, 2019 to Feb 15, 2020	109	ICU admission
Fan, 2020 ¹⁵	Singapore	Singapore	Singapore	NR	67	ICU admission
Fang, 2020 ¹⁶	China	Anhui	Hefei (Anhui Provincial Hospital)	Jan 22 to Mar 1, 2020	78	Severity of COVID-19
Feng, 2020 ¹⁷	China	Hubei, Shanghai, Anhui	Wuhan (Jin Yin-tan Hospital), Shanghai (Shanghai Public Health Clinical Center), Tongling (Tongling People's Hospital)	Jan 1 to Feb 15, 2020	476	Severity of COVID-19, Mortality

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Gao, 2020 ¹⁸	China	Anhui	Fuyang (Second People's Hospital of Fuyang)	Jan 23 to Feb 2, 2020	43	Severity of COVID-19
Gao, 2020 ¹⁹	China	Hubei	Wuhan (RenMin Hospital)	NR	54	Mortality
Gong, 2020 ²⁰	China	Guangdong, Hubei	Guangzhou (Guangzhou Eighth People's Hospital, Third Affiliated Hospital of Sun Yat-sen University), Wuhan (Zhongnan Hospital)	Jan 20 to Mar 2, 2020	189	Severity of COVID-19
Goyal, 2020 ²¹	USA	New York	New York	Mar 3 to Mar 27, 2020	393	Need for mechanical ventilation
Guan, 2020 ²²	China	Nation-wide	Nation-wide	Dec 11, 2019 to Jan 29, 2020	1099	Severity of COVID-19, Composite outcome
Guan, 2020 ²³	China	Nation-wide	Nation-wide	Dec 11, 2019 to Jan 31, 2020	1590	Mortality, Severity of COVID-19, ICU admission, Mechanical ventilation, Composite outcome

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Guo, 2020 ²⁴	China	Hubei	Wuhan (Union Hospital)	Feb 10 to Feb 29, 2020	174	Mortality
Guo, 2020 ²⁵	China	Hubei	Wuhan (Seventh Hospital of Wuhan)	Jan 23 to Feb 23, 2020	187	Mortality
Han, 2020 ²⁶	China	Hubei	Wuhan (RenMin Hospital)	Jan 1 to Feb 18, 2020	273	Severity of COVID-19
Huang, 2020 ²⁷	China	Hubei	Wuhan (Jin Yin-tan Hospital)	Dec 31, 2019 to Jan 2, 2020	41	ICU admission
Ji, 2020 ²⁸	China	Anhui, Beijing	Fuyang (Second People's Hospital of Fuyang), Beijing (Fifth Medical Center of Chinese PLA General hospital)	Jan 20 to Feb 18, 2020	202	Progression of disease
Ji, 2020 ²⁹	China	Anhui, Beijing	Fuyang (Second People's Hospital of Fuyang), Beijing (Fifth Medical Center of Chinese PLA General hospital)	Jan 20 to Feb 22, 2020	208	Progression of disease
Jin, 2020 ³⁰	China	Zhejiang	NR	Jan 17 to Feb 8, 2020	651	Severity of COVID-19
To, 2020 ³¹	Hong Kong	Hong Kong	Hong Kong (Princess Margaret Hospital, Queen Mary Hospital)	NR	23	Composite outcome
Li, 2020 ³²	China	Hubei	Wuhan (Tianyou Hospital of Wuhan)	Jan 18 to Feb 26, 2020	132	Severity of COVID-19

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Li, 2020 ³³	China	Hubei	Wuhan (Tongji Hospital)	Jan 1 to Feb 20, 2020	25	Mortality, Severity of COVID-19
Li, 2020 ³⁴	China	Chongqing, Shandong	Chongqing, Jinan	Jan to Feb 2020	83	Severity of COVID-19
Li, 2020 ³⁵	China	Hubei	Wuhan (Tongji Hospital)	Jan 26 to Feb 5, 2020	548	Mortality, Severity of COVID-19
Li, 2020 ³⁶	China	Hubei	Hanchuan (Hanchuan City People's Hospital)	Jan 20 to Feb 14, 2020	225	Severity of COVID-19
Lian, 2020 ³⁷	China	Zhejiang	NR	Jan 17 to Feb 12, 2020	788	Severity of COVID-19
Lighter, 2020 ³⁸	USA	New York	New York	March 4 to April 4, 2020	3615	Hospital admission, ICU admission
Liu, 2020 ³⁹	China	Anhui	Hefei, Bozhou, Tongling, Fuyang	Jan 21 to Feb 3, 2020	73	Severity of COVID-19
Liu, 2020 ⁴⁰	China	Hubei	Wuhan	Dec 30, 2019 to Jan 15, 2020	78	Progression of disease
Liu, 2020 ⁴¹	China	Hubei	Wuhan (Zhongnan Hospital)	Jan 1 to Feb 29, 2020	245	Mortality
Liu, 2020 ⁴²	China	Hubei	Wuhan (Central Hospital of Wuhan)	Jan 2 to Mar 1, 2020	383	Mortality

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Liu, 2020 ⁴³	China	Hubei	Wuhan (RenMin Hospital)	Jan 31 to Feb 26, 2020	119	Severity of COVID-19
Lyu, 2020 ⁴⁴	China	Henan	Zhengzhou (First Affiliated Hospital of Zhengzhou)	Jan 15 to Feb 24, 2020	51	Severity of COVID-19
Mao, 2020 ⁴⁵	China	Hubei	Wuhan (Union Hospital)	Jan 16 to Feb 19, 2020	214	Severity of COVID-19
Meng, 2020 ⁴⁶	China	Hubei	Wuhan (RenMin Hospital)	Jan 1 to Feb 23, 2020	58	Progression of disease
Mo, 2020 ⁴⁷	China	Hubei	Wuhan (Zhongnan Hospital)	Jan 1 to Feb 5, 2020	155	Progression of disease
Nobel, 2020 ⁴⁸	USA	New York	New York	Mar 10 to Mar 21, 2020	278	Hospital admission, ICU admission
Pan, 2020 ⁴⁹	China	Hubei	Wuhan (Hanan Hospital, Union Hospital), Huanggang (Huanggang Central Hospital)	Jan 18 to Feb 28, 2020	103	Severity of COVID-19
Qin, 2020 ⁵⁰	China	Hubei	Wuhan (Tongji Hospital)	Jan 10 to Feb 12, 2020	452	Severity of COVID-19
Qiu, 2020 ⁵¹	China	Zhejiang	Ningbo (Ningbo Women and Children's Hospital), Wenzhou (Third Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital of Wenzhou)	NR	36	Severity of COVID-19

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Shen, 2020 ⁵²	China	Hubei	Xiangyang (Xiangyang Central Hospital)	Jan to Feb 2020	119	ICU admission
Shen, 2020 ⁵³	China	Shaanxi	NR	Jan 22 to Feb 7, 2020	44	Severity of COVID-19
Shi, 2020 ⁵⁴	China	Zhejiang	NR	NR	487	Severity of COVID-19
Shi, 2020 ⁵⁵	China	Hubei	Wuhan (RenMin Hospital)	Jan 20 to Feb 10, 2020	416	Mortality
Simonnet, 2020 ⁵⁶	France	Lille	Lille (Roger Salengro Hospital)	Feb 27 to Apr 5, 2020	124	Need for mechanical ventilation
Tang, 2020 ⁵⁷	China	Hubei	Wuhan (Tongji Hospital)	Jan 1 to Feb 13, 2020	449	Mortality
Tian, 2020 ⁵⁸	China	Beijing	Beijing (Beijing Emergency Medical Center, Beijing Chao Yang District Emergency Medical Center, Beijing Haidian District Medical Rescue Center, Beijing Luhe Hospital, Beijing Dongcheng District Emergency Medical Center, Beijing Shijingshan District Hospital, Beijing Daxing District People's Hospital)	Jan 20 to Feb 10, 2020	262	Severity of COVID-19

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Wan, 2020 ⁵⁹	China	Chongqing	Chongqing (Three Gorges Hospital)	Jan 23 to Feb 8, 2020	135	Severity of COVID-19
Wang, 2020 ⁶⁰	China	Hubei	Wuhan (Tongji Hospital)	Jan 25 to Feb 25, 2020	344	Mortality
Wang, 2020 ⁶¹	China	Hubei	Wuhan (RenMin Hospital)	Jan 1 to Feb 6, 2020	339	Mortality
Wang, 2020 ⁶²	China	Guangdong	Shenzhen (Third People's Hospital of Shenzhen)	Jan 11 to Feb 29, 2020	55	Severity of COVID-19
Wang, 2020 ⁶³	China	Hubei	Wuhan (Union Hospital)	Jan 16 to Jan 29, 2020	67	Low SpO ₂
Wang, 2020 ⁶⁴	China	Hubei	Wuhan (Zhongnan Hospital)	NR	138	ICU admission
Wang, 2020 ⁶⁵	China	Hubei	Wuhan (RenMin Hospital)	Jan 14 to Feb 13, 2020	116	Severity of COVID-19
Wu, 2020 ⁶⁶	China	Jiangsu, Anhui	Yancheng (First People's Hospital of Yancheng City, Second People's Hospital of Yancheng City), Fuyang (Second People's Hospital of Fuyang City), Wuxi (Fifth People's Hospital of Wuxi)	Jan 20 to Feb 19, 2020	280	Severity of COVID-19
Wu, 2020 ⁶⁷	China	Hubei	Wuhan (Jin Yin-tan Hospital)	Dec 25, 2019 to Jan 26, 2020	201	ARDS

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Xie, 2020 ⁶⁸	China	Hubei	Wuhan (Jin Yin-tan Hospital)	Feb 2 to Feb 23, 2020	79	Severity of COVID-19
Xu, 2020 ⁶⁹	China	Hebei	Baoding (Affiliated Hospital of Hebei University, Baoding City People's Hospital)	Jan to Feb 2020	50	Severity of COVID-19
Yang, 2020 ⁷⁰	China	Shanghai	Shanghai (Shanghai Public Health Clinical Center)	NR	273	Progression of disease
Yang, 2020 ⁷¹	China	Hubei	Wuhan (Jin Yin-tan Hospital)	Dec 24, 2019 to Jan 26, 2020	52	Mortality
Yang, 2020 ⁷²	China	Hubei	Wuhan (Jin-Yin-tan Hospital)	Late Dec 2019 to Feb 25, 2020	1476	Mortality
Yang, 2020 ⁷³	China	Zhejiang, Jiangxi	Hangzhou (Zhejiang Xiaoshan Hospital), Nanchang (First Affiliated Hospital of Nanchang University)	NR	93	Severity of COVID-19
Young, 2020 ⁷⁴	Singapore	Singapore	NR	Jan 23 to Feb 3, 2020	18	Need for supplemental oxygen
Yuan, 2020 ⁷⁵	China	Guangdong	Shenzhen (Third People's Hospital of Shenzhen)	Jan 11 to Feb 4, 2020	94	Severity of COVID-19
Yuan, 2020 ⁷⁶	China	Hubei	Wuhan (Central Hospital of Wuhan)	Jan 1 to Jan 25, 2020	27	Mortality

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Zhao, 2020 ⁷⁷	China	Hunan	Changsa (Second Xiangya Hospital, First Hospital of Changsha)	Jan 16 to Feb 4, 2020	118	Progression of disease
Zhang, 2020 ⁷⁸	China	Hubei	Wuhan (Xinzhou District People's Hospital)	Jan 16 to Feb 25, 2020	95	Severity of COVID-19, Composite outcome
Zhang, 2020 ⁷⁹	China	Hubei	Wuhan (Zhongnan Hospital)	Jan 18 to Feb 22, 2020	115	Severity of COVID-19
Zhang, 2020 ⁸⁰	China	Hubei	Wuhan (Seventh Hospital of Wuhan)	Jan 16 to Feb 3, 2020	140	Severity of COVID-19
Zhang, 2020 ⁸¹	China	Zhejiang	NR	Jan 17 to Feb 8, 2020	645	Severity of COVID-19
Zhang, 2020 ⁸²	China	Hubei	Wuhan (RenMin Hospital)	Jan 11 to Feb 6, 2020	663	Severity of COVID-19, Mortality, Progression of disease
Zhang, 2020 ⁸³	China	Hubei	Wuhan (RenMin Hospital)	Jan 10 to Feb 10, 2020	120	Severity of COVID-19
Zhao, 2020 ⁸⁴	China	Hunan	Changsha, Yueyang, Changde, Xiang-Tan	NR	101	Severity of COVID-19

Reference	Country	Region	City (Hospital)	Recruitment period	Sample size	Outcomes
Zheng, 2020 ⁸⁵	China	Hunan	Changsha (North Hospital of Changsha)	Jan 17 to Feb 7, 2020	161	Severity of COVID-19
Zhou, 2020 ⁸⁶	China	Jiangxi	Nanchang (Ninth Hospital of Nanchang)	Jan 28 to Feb 6, 2020	17	Progression of disease
Zhou, 2020 ⁸⁷	China	Hubei	Wuhan (Jin Yin-tan Hospital, Pulmonary Hospital of Wuhan)	Dec 29, 2019 to Jan 31, 2020	191	Mortality
Zhou, 2020 ⁸⁸	China	Hubei	Wuhan (Central Hospital of Wuhan)	Dec 20, 2019 to Feb 9, 2020	254	Mortality

Supplementary Table 2. Meta-analyses of observational studies for risk factors of adverse clinical outcomes in patients with COVID-19 that were examined in 2 independent studies.

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
<i>ICU admission (Yes vs. No)</i>						
Age	>65 vs. <65	71/228	2	2.81 (0.26 - 31.02)	0.398	92
Albumin	Decreased vs. Normal	73/358	2	1.75 (0.76 - 4.02)	0.188	57
AST	Elevated vs. Normal	64/150	2	2.15 (0.60 - 7.70)	0.239	62
Bilateral lung involvement	Yes vs. No	49/179	2	0.83 (0.07 - 10.20)	0.881	0
COPD	Yes vs. No	49/179	2	8.33 (1.27 - 54.56)	0.027	0
Creatinine	Elevated vs. Normal	64/150	2	0.62 (0.05 - 7.03)	0.697	71
Hemoptysis	Yes vs. No	64/148	2	3.23 (0.77 - 13.45)	0.108	0
Highest temperature	>39 vs. <39	64/150	2	1.47 (0.09 - 23.69)	0.788	65
LDH	Elevated vs. Normal	17/70	2	12.12 (2.04 - 71.81)	0.006	0
Myalgia	Yes vs. No	87/247	2	1.35 (0.57 - 3.23)	0.495	45
Nausea and/or vomiting	Yes vs. No	64/397	2	0.80 (0.37 - 1.73)	0.563	0
Neutrophil count	Decreased vs. Normal	60/174	2	0.35 (0.04 - 3.22)	0.352	8
Pharyngalgia	Yes vs. No	56/257	2	1.66 (0.23 - 12.16)	0.616	68

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
Respiratory rate	Elevated vs. Normal	64/150	2	3.31 (0.52 - 21.02)	0.205	78
Troponin	Elevated vs. Normal	64/150	2	2.80 (0.29 - 27.41)	0.376	73
WBC	>10 vs. <10	64/149	2	2.18 (0.54 - 8.80)	0.274	65
<i>Progression of disease (Yes vs. No)</i>						
Abdominal pain	Yes vs. No	497/818	2	1.35 (0.29 - 6.37)	0.701	0
Age	Per 1 unit increase	143/453	2	1.05 (1.00 - 1.11)	0.074	81
ALT	Elevated vs. Normal	451/865	2	1.51 (0.66 - 3.49)	0.331	77
Any gastrointestinal disease	Yes vs. No	457/781	2	1.60 (0.45 - 5.76)	0.469	35
Any respiratory disease	Yes vs. No	457/781	2	2.23 (1.18 - 4.24)	0.014	0
AST	Elevated vs. Normal	451/865	2	2.37 (1.65 - 3.39)	2.5×10^{-6}	0
Cardiovascular disease	Yes vs. No	497/818	2	6.25 (1.10 - 35.45)	0.039	48
COPD	Yes vs. No	95/213	2	10.53 (1.18 - 93.84)	0.035	0
Dizziness	Yes vs. No	497/818	2	3.95 (1.26 - 12.39)	0.019	0
LDH	Per 1 unit increase	90/172	2	0.998 (0.994 - 1.002)	0.306	0
LDH	Elevated vs. Normal	452/871	2	4.79 (3.50 - 6.56)	1.8×10^{-22}	0
Malignancy	Yes vs. No	497/818	2	2.21 (0.80 - 6.13)	0.127	0
Myalgia	Yes vs. No	497/818	2	0.40 (0.26 - 0.61)	1.9×10^{-5}	1

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
Nausea	Yes vs. No	497/818	2	0.82 (0.11 - 5.84)	0.839	49
Smoking status	Ever vs. Never	125/363	2	1.98 (0.82 - 4.82)	0.131	0
Urinary system disease	Yes vs. No	457/781	2	4.23 (1.35 - 13.26)	0.013	0
Vomiting	Yes vs. No	497/818	2	1.28 (0.49 - 3.32)	0.618	0
<i>Mortality (Yes vs. No)</i>						
Age	>65 vs. <65	134/880	2	4.37 (1.14 - 16.74)	0.032	80
ALT	Per 1 unit increase	98/584	2	1.004 (0.997 - 1.012)	0.230	60
Altered consciousness	Yes vs. No	138/937	2	19.27 (5.70 - 65.10)	1.9×10^{-6}	8
Autoimmune disease	Yes vs. No	178/613	2	1.19 (0.21 - 6.69)	0.847	0
Blood glucose	Elevated vs. Normal	51/107	2	0.89 (0.39 - 2.05)	0.788	0
BUN	Elevated vs. Normal	130/802	2	7.29 (5.09 - 10.43)	1.9×10^{-27}	0
Chronic liver disease	Yes vs. No	98/584	2	3.03 (0.72 - 12.74)	0.131	0
CK	Elevated vs. Normal	71/223	2	2.09 (0.95 - 4.59)	0.065	0
Consolidation	Yes vs. No	64/218	2	3.26 (1.16 - 9.13)	0.025	20
CRP	Per 1 unit increase	98/584	2	1.015 (1.011 - 1.020)	1.5×10^{-10}	16
D-dimer	Per 1 unit increase	199/788	2	1.03 (0.99 - 1.08)	0.095	86
Heart rate	Elevated vs. Normal	167/465	2	2.79 (0.97 - 7.97)	0.056	17
Heart rate	Per 1 unit increase	98/584	2	1.020 (1.003 - 1.036)	0.018	42

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
Hemoglobin	Decreased vs. Normal	79/854	2	1.66 (0.57 - 4.86)	0.354	70
Hemoptysis	Yes vs. No	134/453	2	1.23 (0.27 - 5.58)	0.784	12
Interleukin-6	Elevated vs. Normal	72/218	2	5.39 (0.05 - 599.57)	0.484	90
Local patchy opacity/shadowing	Yes vs. No	132/416	2	0.23 (0.07 - 0.83)	0.025	50
Nausea and vomiting	Yes vs. No	63/469	2	0.79 (0.08 - 7.94)	0.841	54
PaO ₂	Decreased vs. Normal	56/246	2	11.62 (0.73 - 183.63)	0.082	72
PaO ₂ /FiO ₂	Decreased vs. Normal	56/246	2	10.92 (0.30 - 400.25)	0.193	83
Pharyngalgia	Yes vs. No	178/613	2	0.93 (0.38 - 2.27)	0.867	0
Platelet count	Per 1 unit increase	199/788	2	0.995 (0.992 - 0.998)	3.3 × 10 ⁻⁴	56
Pleural effusion	Yes vs. No	29/82	2	0.75 (0.22 - 2.60)	0.654	0
SBP	<90 vs. >90	167/465	2	3.77 (0.72 - 19.77)	0.116	15
SpO ₂	Decreased vs. Normal	118/341	2	17.72 (4.71 - 66.70)	2.1 × 10 ⁻⁵	27
Tuberculosis	Yes vs. No	40/234	2	1.40 (0.10 - 18.93)	0.800	31
<i>Severity of disease (Severe/Critical vs. Mild/Moderate)</i>						
Any neurological disease	Yes vs. No	120/383	2	2.22 (0.30 - 16.44)	0.434	6
Any neurological symptom	Yes vs. No	194/654	2	1.51 (0.86 - 2.62)	0.148	36
Asthma	Yes vs. No	271/603	2	2.15 (0.44 - 10.59)	0.345	0

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
Cardiovascular and/or cerebrovascular diseases	Yes vs. No	171/494	2	4.38 (0.42 - 45.96)	0.218	93
Chest tightness	Yes vs. No	589/1088	2	1.78 (1.03 - 3.06)	0.038	72
Chills	Yes vs. No	117/428	2	1.71 (0.71 - 4.12)	0.234	0
Fatty liver disease	Yes vs. No	95/243	2	1.24 (0.34 - 4.60)	0.743	0
Globulin	Elevated vs. Normal	296/655	2	2.15 (1.56 - 2.97)	3.5×10^{-6}	0
Highest temperature	>39 vs. <39	59/312	2	1.16 (0.28 - 4.77)	0.839	0
INR	Elevated vs. Normal	95/760	2	2.99 (0.42 - 21.28)	0.274	66
Linear opacity	Yes vs. No	140/525	2	3.35 (0.53 - 20.99)	0.197	81
Mixed ground-glass opacity and consolidation	Yes vs. No	27/142	2	1.53 (0.55 - 4.27)	0.413	17
Neutrophil count	Decreased vs. Normal	292/625	2	0.55 (0.12 - 2.56)	0.444	64
Pleural thickening	Yes vs. No	156/494	2	1.04 (0.69 - 1.58)	0.845	0
Proteinuria	Yes vs. No	189/449	2	2.95 (1.95 - 4.46)	3.0×10^{-7}	0
Respiratory rate	Elevated vs. Normal	51/156	2	9.99 (2.87 - 34.84)	3.0×10^{-4}	0
Retching/Belching	Yes vs. No	97/274	2	0.79 (0.20 - 3.09)	0.738	0
Reticulation	Yes vs. No	39/184	2	2.86 (1.01 - 8.14)	0.049	0
Rhinorrhea	Yes vs. No	369/732	2	1.73 (0.84 - 3.59)	0.138	0

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
SpO2	Decreased vs. Normal	293/629	2	15.67 (6.67 - 36.81)	2.7×10^{-10}	48
Troponin	Elevated vs. Normal	84/298	2	5.77 (2.57 - 12.92)	2.1×10^{-5}	0
Tuberculosis	Yes vs. No	327/688	2	1.56 (0.22 - 10.88)	0.652	39
<i>Composite outcome (Yes vs. No)</i>						
Age	>65 vs. <65	173/1247	2	5.05 (2.93 - 8.68)	5.0×10^{-9}	51
ALT	Elevated vs. Normal	59/764	2	1.45 (0.23 - 9.15)	0.691	60
Any comorbidity	Yes vs. No	141/1613	2	5.04 (3.51 - 7.24)	1.8×10^{-18}	0
Chest pain	Yes vs. No	41/135	2	18.28 (1.43 - 234.51)	0.026	28
Chills	Yes vs. No	77/1122	2	1.08 (0.53 - 2.22)	0.830	0
Chronic respiratory disease	Yes vs. No	118/259	2	1.63 (0.83 - 3.18)	0.153	0
Creatinine	Elevated vs. Normal	62/775	2	5.83 (0.94 - 36.37)	0.059	40
Diarrhea	Yes vs. No	77/1122	2	1.95 (0.71 - 5.32)	0.194	0
Hypertension	Yes vs. No	141/1613	2	1.63 (1.11 - 2.38)	0.012	0
Malignancy	Yes vs. No	239/1826	2	3.53 (2.03 - 6.14)	8.1×10^{-6}	0
Myalgia	Yes vs. No	77/1122	2	1.33 (0.11 - 15.80)	0.822	61
Nasal congestion	Yes vs. No	77/1122	2	0.56 (0.15 - 2.07)	0.381	0
Pharyngalgia	Yes vs. No	77/1122	2	0.81 (0.20 - 3.34)	0.772	22
Smoking status	Yes vs. No	103/1166	2	3.04 (1.91 - 4.84)	3.0×10^{-6}	0
WBC	<4 vs. >4	68/1001	2	0.45 (0.12 - 1.72)	0.244	42

Risk factor	Level of comparison	N cases/N participants	N studies	Random-effects summary OR (95% CI)	P-value	I²
<i>Invasive mechanical ventilation (Yes vs. No)</i>						
Diabetes mellitus	Yes vs. No	215/517	2	1.50 (0.78 - 2.85)	0.221	35
Hypertension	Yes vs. No	215/517	2	1.78 (0.78 - 4.03)	0.169	70
Sex	Male vs. Female	215/517	2	1.84 (1.24 - 2.73)	0.003	0

Supplementary References

1. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy*. April 2020. doi:10.1111/all.14309
2. Cao J, Tu W-J, Cheng W, et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. *Clin Infect Dis*. April 2020. doi:10.1093/cid/ciaa243
3. Caruso D, Zerunian M, Polici M, et al. Chest CT Features of COVID-19 in Rome, Italy. *Radiology*. April 2020:201237. doi:10.1148/radiol.2020201237
4. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;130(5):2620-2629. doi:10.1172/JCI137244
5. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091. doi:10.1136/bmj.m1091
6. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect*. 2020;80(5):e1-e6. doi:10.1016/j.jinf.2020.03.004
7. Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. *Journals Gerontol Ser A*. April 2020. doi:10.1093/gerona/glaa089
8. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *Clin Infect Dis*. April 2020. doi:10.1093/cid/ciaa449
9. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020;97(5):829-838. doi:10.1016/j.kint.2020.03.005
10. Chu J, Yang N, Wei Y, et al. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. *J Med*

- Virol.* April 2020:jmv.25793. doi:10.1002/jmv.25793
11. Colombi D, Bodini FC, Petrini M, et al. Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia. *Radiology.* 2020:201433. doi:10.1148/radiol.2020201433
 12. Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *Int J Cardiol.* April 2020. doi:10.1016/j.ijcard.2020.03.087
 13. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. *Eur Respir J.* April 2020. doi:10.1183/13993003.00524-2020
 14. Du R-H, Liu L-M, Yin W, et al. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. *Ann Am Thorac Soc.* April 2020. doi:10.1513/AnnalsATS.202003-225OC
 15. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. *Am J Hematol.* March 2020. doi:10.1002/ajh.25774
 16. Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. *J Infect.* April 2020. doi:10.1016/j.jinf.2020.03.039
 17. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. *Am J Respir Crit Care Med.* April 2020. doi:10.1164/rccm.202002-0445OC
 18. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol.* March 2020. doi:10.1002/jmv.25770
 19. Gao L, Jiang D, Wen X, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. *Respir Res.* 2020;21(1):83. doi:10.1186/s12931-020-01352-w
 20. Gong J, Ou J, Qiu X, et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. *Clin Infect Dis.* April 2020.

- doi:10.1093/cid/ciaa443
21. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. *N Engl J Med*. April 2020. doi:10.1056/NEJMc2010419
 22. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
 23. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J*. March 2020:2000547. doi:10.1183/13993003.00547-2020
 24. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev*. March 2020:e3319. doi:10.1002/dmrr.3319
 25. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. March 2020. doi:10.1001/jamacardio.2020.1017
 26. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *J Med Virol*. April 2020. doi:10.1002/jmv.25809
 27. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
 28. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol*. April 2020. doi:10.1016/j.jhep.2020.03.044
 29. Ji D, Zhang D, Xu J, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. *Clin Infect Dis*. April 2020. doi:10.1093/cid/ciaa414
 30. Jin X, Lian J-S, Hu J-H, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. March 2020. doi:10.1136/gutjnl-2020-

31. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20(5):565-574. doi:10.1016/S1473-3099(20)30196-1
32. Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. *J Infect.* April 2020. doi:10.1016/j.jinf.2020.03.035
33. Li Y, Peng S, Li L, et al. Clinical and Transmission Characteristics of Covid-19 — A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department. *Curr Med Sci.* 2020;40(2):295-300. doi:10.1007/s11596-020-2176-2
34. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. *Invest Radiol.* 2020;55(6):327-331. doi:10.1097/RLI.0000000000000672
35. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* April 2020. doi:10.1016/j.jaci.2020.04.006
36. Li R, Tian J, Yang F, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China. *J Clin Virol.* 2020;127:104363. doi:10.1016/j.jcv.2020.104363
37. Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. *Clin Infect Dis.* March 2020. doi:10.1093/cid/ciaa242
38. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clin Infect Dis.* April 2020. doi:10.1093/cid/ciaa415
39. Liu K-C, Xu P, Lv W-F, et al. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. *Eur J Radiol.* 2020;126:108941. doi:10.1016/j.ejrad.2020.108941

40. Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)*. 2020;133(9):1032-1038. doi:10.1097/CM9.0000000000000775
41. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. April 2020. doi:10.1016/j.jinf.2020.04.002
42. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. *Platelets*. April 2020:1-7. doi:10.1080/09537104.2020.1754383
43. Liu R, Ma Q, Han H, et al. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019. *Clin Chem Lab Med*. April 2020. doi:10.1515/cclm-2020-0220
44. Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia. *Invest Radiol*. April 2020:1. doi:10.1097/RLI.0000000000000689
45. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. April 2020. doi:10.1001/jamaneurol.2020.1127
46. Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. *J Infect*. April 2020. doi:10.1016/j.jinf.2020.04.004
47. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. March 2020. doi:10.1093/cid/ciaa270
48. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States. *Gastroenterology*. April 2020. doi:10.1053/j.gastro.2020.04.017
49. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China. *Am J Gastroenterol*. 2020;115(5):766-773. doi:10.14309/ajg.0000000000000620

50. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. March 2020. doi:10.1093/cid/ciaa248
51. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis*. March 2020. doi:10.1016/S1473-3099(20)30198-5
52. Shen L, Li S, Zhu Y, et al. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China. *J Infect*. April 2020. doi:10.1016/j.jinf.2020.03.038
53. Shen C, Yu N, Cai S, et al. Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease 2019. *J Pharm Anal*. 2020;10(2):123-129. doi:10.1016/j.jpha.2020.03.004
54. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care*. 2020;24(1):108. doi:10.1186/s13054-020-2833-7
55. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol*. March 2020. doi:10.1001/jamacardio.2020.0950
56. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)*. April 2020. doi:10.1002/oby.22831
57. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18(5):1094-1099. doi:10.1111/jth.14817
58. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. *J Infect*. 2020;80(4):401-406. doi:10.1016/j.jinf.2020.02.018
59. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19

- patients in northeast Chongqing. *J Med Virol*. March 2020.
doi:10.1002/jmv.25783
60. Wang Y, Lu X, Chen H, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. *Am J Respir Crit Care Med*. April 2020.
doi:10.1164/rccm.202003-0736LE
 61. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect*. March 2020. doi:10.1016/j.jinf.2020.03.019
 62. Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. *J Infect Dis*. March 2020. doi:10.1093/infdis/jiaa119
 63. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis*. March 2020.
doi:10.1093/cid/ciaa272
 64. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. February 2020. doi:10.1001/jama.2020.1585
 65. Wang L, Li X, Chen H, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. *Am J Nephrol*. March 2020:1-6. doi:10.1159/000507471
 66. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). *J Intern Med*. March 2020. doi:10.1111/joim.13063
 67. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. March 2020.
doi:10.1001/jamainternmed.2020.0994
 68. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A

- retrospective study. *Liver Int.* April 2020. doi:10.1111/liv.14449
69. Xu Y-H, Dong J-H, An W-M, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. *J Infect.* 2020;80(4):394-400. doi:10.1016/j.jinf.2020.02.017
 70. Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. *Aging (Albany NY).* 2020;12(7):6037-6048. doi:10.18632/aging.102999
 71. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* February 2020. doi:10.1016/S2213-2600(20)30079-5
 72. Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. *J Thromb Haemost.* May 2020. doi:10.1111/jth.14848
 73. Yang A-P, Liu J, Tao W, Li H. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol.* 2020;84:106504. doi:10.1016/j.intimp.2020.106504
 74. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA.* March 2020. doi:10.1001/jama.2020.3204
 75. Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res.* 2020;69(6):599-606. doi:10.1007/s00011-020-01342-0
 76. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. *PLoS One.* 2020;15(3):e0230548. doi:10.1371/journal.pone.0230548
 77. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. *Theranostics.* 2020;10(10):4606-4613. doi:10.7150/thno.45016
 78. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical

- characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res.* 2020;21(1):74. doi:10.1186/s12931-020-01338-8
79. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int.* April 2020. doi:10.1111/liv.14455
 80. Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy.* February 2020. doi:10.1111/all.14238
 81. Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis.* 2020;94:81-87. doi:10.1016/j.ijid.2020.03.040
 82. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect.* April 2020. doi:10.1016/j.cmi.2020.04.012
 83. Zhang R, Ouyang H, Fu L, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. *Eur Radiol.* April 2020. doi:10.1007/s00330-020-06854-1
 84. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol.* 2020;214(5):1072-1077. doi:10.2214/AJR.20.22976
 85. Zheng F, Tang W, Li H, Huang Y-X, Xie Y-L, Zhou Z-G. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *Eur Rev Med Pharmacol Sci.* 2020;24(6):3404-3410. doi:10.26355/eurrev_202003_20711
 86. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. *Ann Palliat Med.* 2020;9(2):428-436. doi:10.21037/apm.2020.03.26

87. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
88. Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of Gastrointestinal Symptoms on Patients Infected With Coronavirus Disease 2019. *Gastroenterology*. March 2020. doi:10.1053/j.gastro.2020.03.020